How bad will this year’s flu season be in the United States? At the moment, we have no answer to that important question.

Comedian Kim Soo-yong, who suddenly lost consciousness and collapsed during a recent YouTube filming, has drawn media ...

For patients with acute coronary syndrome, targeted vitamin D3 supplementation is associated with a reduced risk for follow-up myocardial infarction.

A low dose of colchicine — a commonly used gout drug — helped reduce the risk of heart attack and stroke in people with ...

The United States is facing a demographic shift as the population of older adults grows rapidly, with the proportion of ...

Researchers sought to determine the most appropriate P2Y12 inhibitor therapy in patients with acute coronary syndrome.

A inhibitors does not trigger MACEs when compared with TNF- α inhibitors in the 6 months following treatment initiation.

The phase 3 Librexia ACS trial evaluating the safety and efficacy of milvexian after a recent acute coronary syndrome has been discontinued.

Milvexian’s failure in acute coronary syndrome dampens the outlook for other anticoagulants like it and is the latest in a ...

BMS and J&J first linked together in 2018 to develop factor X1a inhibitors as anti-coagulants. The three Phase III Librexia ...

Bristol Myers Squibb and Johnson & Johnson said on Friday they would stop a late-stage trial of their experimental blood clot drug in heart attack patients, after an independent review found the study ...